Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Increases speed to market for drug developers working on nucleic acid therapeutics
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
This artificial RNA ligase has higher thermostability than natural RNA ligase
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
Subscribe To Our Newsletter & Stay Updated
